One of Dr. Yang’s primary research interests is developing AI therapeutics to treat movement disorders, neurodegenerative diseases, and other neurological conditions. In particular, he is interested in the type II artificial intelligence his team has pioneered, where the brain and AI co‑adapt and cooperate to enable therapeutic outcomes. He is deeply engaged in exploring how future AI therapeutics could transform healthcare. Under his leadership, Fasikl successfully developed the first and only FDA‑approved AI therapeutic for essential tremor, a common movement disorder.

Dr. Yang’s second major research area is nerve–computer interfaces. His team has developed cutting‑edge technology capable of recording human peripheral nerve signals and performing simultaneous neural recording and stimulation, enabling the collection of large neural datasets for AI modeling. This work has been translated into the Fasikl‑X research division’s MindForce Nerve Computer Interface, which has received two FDA breakthrough device designations: one for controlling prosthetic devices and computer cursors, and another for treating post‑amputation pain.